Enrolling By InvitationNCT06194799
A 52-Week, Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Medication studyAges 55–95Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 55 years to 95 years.
- Listed locations
- Costa Mesa and 75 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 23, 2024
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 752
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Brazil, ...
- Age range
- From 55 Years to 95 Years
- Official registry ID
- NCT06194799
- Official title
Show the full official title
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruitment & locations
By invitationCosta Mesa, United States · Fresno, United States · Garden Grove, United States
46 more locations
- Aventura, United States
- Hialeah, United States
- Miami, United States
- Miami Gardens, United States
- Miami Lakes, United States
- Abington, United States
- Cypress, United States
- Houston, United States
- Porto Alegre, Brazil
- Brasília, Brazil
- Curitiba, Brazil
- Passo Fundo, Brazil
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Cherven Bryag, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Sofia, Bulgaria
- Antofagasta, Chile
- Santiago, Chile
- Brno, Czechia
- Kladno, Czechia
- Prague, Czechia
- Rychnov nad Kněžnou, Czechia
- Paris, France
- Toulouse, France
- Brescia, Italy
- Salerno, Italy
- Tricase, Italy
- Monterrey, Mexico
- Culiacán, Mexico
- Coahuila, Mexico
- Estado de México, Mexico
- San Luis Potosí City, Mexico
- Belgrade, Serbia
- Gornja Toponica, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Seoul, South Korea
- Incheon, South Korea
- Seville, Spain
- Zamora, Spain
- Kaohsiung City, Taiwan
- Czechia
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including ACP-204.
Who can participate?
Listed age limits: 55 years to 95 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
